Rivastigmine for drug-induced confusion
Part of Brain & nervous system clinical trials.
This study tests whether the drug rivastigmine can help people who are very agitated and confused due to certain drug side effects. If it works, it could calm them down and improve their confusion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 10 years or older
- Have a specific kind of delirium caused by certain drugs or poisons (antimuscarinic delirium)
- Be very agitated and confused (scored +1 or higher on a standard agitation scale)
- Have a family member or friend available to give consent if needed
- Not be pregnant, not have a history of seizures or certain heart rhythm issues, and not be on a breathing machine
- Not have other major health problems like asthma, COPD, stomach ulcers, or a known allergy to rivastigmine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medications, haloperidol and dexmedetomidine, to see which works better for reducing confusion and agitation in patients who are on a breathing machine after a traumatic brain injury. If you or a loved one is in the ICU with a brain injury and is restless or confused, this trial may help find better ways to manage those symptoms.
This study tests whether a small, easy-to-swallow tablet of rivastigmine can help improve memory and thinking in people with moderate Alzheimer's disease. Rivastigmine is a common Alzheimer's medication that may help slow down memory loss.
This Phase 2 trial tests whether melatonin can reduce delirium, a sudden confusion that can happen in the ICU. If you qualify, you may be given melatonin to see if it improves alertness and comfort during an expected longer ICU stay.
This study tests whether using virtual reality (VR) in the ICU can help prevent confusion (delirium) in patients. If you are in the surgical ICU at Cedars-Sinai and are expected to stay more than 2 days, you might be able to participate.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
This study tests a virtual reality program that uses calming sights and sounds to help prevent delirium (a state of confusion) in patients in the intensive care unit (ICU). It may help keep your mind clear during your stay.
Hear when a new Anticholinergic Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.